- Patients EPRs were utilised to generate RWE on treatment patterns and clinical outcomes for patients with aNSCLC in the UK
- 1003 patients who started a first-line treatment for aNSCLC were included from nine UK hospitals
- The evidence highlighted the need for improved treatment options for tumours lacking targetable mutations
to learn more.
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com
and contact us at firstname.lastname@example.org